IMMUNITYBIO, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs ImmunityBio, Inc. (IBRX) Investors of a Securities Fraud Lawsuit

Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026 (the "Class Period").

Investor Deadline: Investors who purchased or acquired ImmunityBio securities during the Class Period may, no later than May 26, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

ImmunityBio, headquartered in San Diego, Calif., develops cancer immunotherapies and vaccines.

According to the lawsuit, the Company's Chief Scientific and Medical Officer materially overstated the capabilities of ImmunityBio's Anktiva platform, rendering prior statements about the Company's business, operations, and prospects materially false and misleading.

When the true state of the Company was revealed, investors who purchased shares during the Class Period suffered losses.

If you are an ImmunityBio investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [e-mail] or [phone], or Caitlin Adorni at [e-mail] or [phone].

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

Andrew Abramowitz
Berger Montague
[phone]
[e-mail]

Caitlin Adorni
Berger Montague
[phone]
[e-mail]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296391

The ImmunityBio Stock at the time of publication of the news with a fall of -5,74 % to 6,73EUR on Tradegate stock exchange (07. Mai 2026, 14:54 Uhr).